Skip to content

Source filing unavailable

Q3 2014 · —
Revenue$306.58M+32.1% vs Q3 2013+5.3% vs Q2 2014
Net Income$25.77M−65.8% vs Q3 2013−41.0% vs Q2 2014
EPS Diluted$0.41−66.7% vs Q3 2013−41.4% vs Q2 2014
Gross Profit$277,413,000+34.6%
Operating Income$58,036,000−42.3%
Operating Cash Flowderived$129,697,000−0.8%
Free Cash Flowderived$121,558,000−5.5%
Margins · derived
Gross margin90.5%+1.7 pt vs Q3 2013
Operating margin18.9%−24.4 pt vs Q3 2013
Net margin8.4%−24.1 pt vs Q3 2013

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2014Q3 2013Q3 2012Q3 2011
Revenue$306.58M$232.16M$175.52M$73.29M
Net Income$25.77M$75.41M$33.21M$32.48M
EPS Diluted$0.41$1.23$0.55$0.69

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR